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A B S T R A C T
Background
Pancreatic necrosis may complicate severe acute pancreatitis, and is detectable by computed tomography (CT). If it becomes infected
mortality increases, but the use of prophylactic antibiotics raises concerns about antibiotic resistance and fungal infection.
Objectives
To determine the eHicacy and safety of prophylactic antibiotics in acute pancreatitis complicated by CT proven pancreatic necrosis.
Search methods
Searches were updated in November 2008, in The Cochrane Library (Issue 2, 2008), MEDLINE, EMBASE, and CINAHL. Conference proceedings
and references from found articles were also searched.
Selection criteria
Randomised controlled trials (RCTs) comparing antibiotics versus placebo in acute pancreatitis with CT proven necrosis.
Data collection and analysis
Primary outcomes were mortality and pancreatic infection rates. Secondary end-points included non pancreatic infection, all sites
infection, operative rates, fungal infections, and antibiotic resistance. Subgroup analyses were performed for antibiotic regimen (beta-
lactam, quinolone, and imipenem).
Main results
Seven evaluable studies randomised 404 patients. There was no statistically significant eHect on reduction of mortality with therapy:
8.4% versus controls 14.4%, and infected pancreatic necrosis rates: 19.7% versus controls 24.4%. Non-pancreatic infection rates and
the incidence of overall infections were not significantly reduced with antibiotics: 23.7% versus 36%; 37.5% versus 51.9% respectively.
Operative treatment and fungal infections were not significantly diHerent. InsuHicient data were provided concerning antibiotic resistance.
With beta-lactam antibiotic prophylaxis there was less mortality (9.4% treatment, 15% controls), and less infected pancreatic necrosis
(16.8% treatment group, 24.2% controls) but this was not statistically significant. The incidence of non-pancreatic infections was non-
significantly diHerent (21% versus 32.5%), as was the incidence of overall infections (34.4% versus 52.8%), and operative treatment rates.
No significant diHerences were seen with quinolone plus imidazole in any of the end points measured. Imipenem on its own showed no
diHerence in the incidence of mortality, but there was a significant reduction in the rate of pancreatic infection (p=0.02; RR 0.34, 95% CI
0.13 to 0.84).
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Authors' conclusions
No benefit of antibiotics in preventing infection of pancreatic necrosis or mortality was found, except for when imipenem (a beta-lactam)
was considered on its own, where a significantly decrease in pancreatic infection was found. None of the studies included in this review
were adequately powered. Further better designed studies are needed if the use of antibiotic prophylaxis is to be recommended.
P L A I N   L A N G U A G E   S U M M A R Y
Use of antibiotics to prevent infection of dead pancreatic tissue in acute pancreatitis
Acute pancreatitis is the inflammation of the pancreas, a serious emergency with no specific treatment. The pancreas, a digestive gland,
can become inflamed for many reasons, but mainly as a complication from gallstones or excess alcohol intake. If severe, the pancreas
may lose its blood supply, a complication called pancreatic necrosis that can be detected by computed tomography (CT) scanning.  Death
can occur either early in the disease process in association with uncontrolled inflammatory responses, causing multiple organ-system
failure (MOSF), or late when the necrotic tissue becomes infected, which might necessitate major surgery to remove the infection, with the
risk of death rising from 10% to over 40%. Antibiotics may prevent later infection and reduce the risk of death, but could also encourage
bacterial antibiotic resistance and fungal infections. Controlled trials looking at the value of using prophylactic antibiotics have produced
conflicting results.
This review aims to determine the eHectiveness and safety of prophylactic antibiotics in CT-proven necrotising acute pancreatitis. A
previous version published in 2006 suggested a survival advantage overall, and a decrease in pancreatic infections for some types of
antibiotic therapy (beta-lactam antibiotics). Since that review, two further studies have been published: both were double-blinded,
randomised, clinical trials (RCTs). These studies have now been included and our conclusions have changed as a result.
In the current review, data were found and analysed from 7 trials involving 404 patients randomly allocated to receive antibiotics or
placebo. Although death occurred less aOer antibiotics (8.4%) than placebo (14.4%), as did infected pancreatic necrosis (19.7% versus
24.4%) and other infections (23.7% versus 36%), the diHerences were not statistically significant and so genuine benefit cannot be
confirmed. There were no major problems with antibiotic resistance, and fungal infections were similar (3.9% versus 5%). The quality of
studies was variable and only two were ‘blinded’, whereby investigators and patients were unaware of which treatment patients received.
Many diHerent regimens were used, and of the two main types of antibiotics used, a beta-lactam appeared to work better. Only one type
of antibiotic (imipenem) was considered on its own, showing a significant decrease in infection of the pancreatic necrosis.
Although we cannot confirm benefit from the use of prophylactic antibiotics in this condition, consistent trends towards a beneficial eHect
nevertheless remain. Further, better designed studies, ideally with beta-lactam antibiotics, are required.
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B A C K G R O U N D
Description of the condition
Acute pancreatitis is a common acute abdominal emergency,
with an apparently rising incidence (Tinto 2002; Goldacre 2004,
Sandzén 2009). No specific treatment is available, and the in-
hospital case mortality rate of 5 to 10% (Bradley 1993) has
remained fairly static for over four decades. Death usually occurs
in association with uncontrolled local and systemic inflammatory
responses, causing pancreatic necrosis and multiple organ-system
failure (MOSF). Management consists of intensive therapy should
MOSF develop, with invasive interventions for complications
of pancreatic necrosis. The mortality risk can increase to as
much as 40% if initially sterile pancreatic necrosis becomes
infected, following which surgical, endoscopic, or percutaneous
debridement is oOen required (Beger 1986; Bradley 1989; Larvin
1989; Larvin 2008; Bradley 1993; Bassi 1994a; Bassi 1994b;
Isenmann 1994; Ho 1997; Dervenis 1999; Farkas 1996; Büchler 2000;
Werner 2003; Werner 2005). The infecting agents are usually gut-
derived bacteria (Garg 2001), and they are thought to migrate
via the pancreatic duct from the duodenum, or from adjacent
bowel either via intervening lymphatics or directly, as gut mucosal
defences against bacterial translocation become impaired in severe
acute pancreatitis (Ammori 1999; Rahman 2003).
It has long been known that pancreatic necrosis can be established
as early as the time of admission to hospital, when contrast-
enhanced computed tomography (CT) is undertaken (Larvin 1990),
but superinfection may later manifest with a second period of
multiple organ-system failure. Thus there exists a window of
opportunity of around 1-2 weeks during which superinfection
may be prevented by administering antibacterial therapy (Beger
1986; Barie 1996; Bassi 1994a; Steinberg 1994). Although
antibiotics known to penetrate viable pancreatic tissue may not
penetrate areas of necrosis eHectively, high microbicidal levels
can be achieved in adjacent tissues (Burns 1986; Büchler 1992;
Bassi 1994b; Bertazzoni 1996; Foitzik 1997; Bassi 1998; Kramer
1999). High circulating levels should also prevent infection via
haematogenous and lymphatic routes (Barie 1996). Attempts have
been made to incorporate gastro-intestinal tract decontamination,
which includes antibacterial agent administration (Luiten 1995;
Luiten 1999). It is feared that the administration of potent
antibacterial therapy for 2 weeks or more could potentially increase
the risks of antibacterial resistance and facilitate opportunistic
fungal infection (Eatock 1999).
Description of the intervention
Following a relatively small number of controlled and uncontrolled
trials, enthusiasm for prophylaxis was expressed through a number
of influential journal articles and editorials (Bradley 1989; Johnson
1996; Foxx-Orenstein 1997; Golub 1998; Powell 1998; Bradley
1999; Ratschko 1999; Rünzi 1999). A United Kingdom (UK) survey
suggested that almost 90% of surgeons applied prophylaxis (Powell
1999). Although trials were underpowered and generated variable
results, meta-analyses suggested that mortality or morbidity could
be reduced (Powell 1999; Golub 1998; Sharma 2001). However,
there has been increasing concern over adverse eHects. Some
11% of specialists responding to the above mentioned UK survey
reported adverse eHects attributable to antibiotic administration
(Powell 1999), including antimicrobial resistance and opportunistic
fungal infection aHecting excised necrotic sequestra, blood and
remote sites.
There has been a steady rise in the emergence of resistant
organisms in general, but there are few reliable sources of data
on whether increased antibacterial prophylaxis is associated with
rising antimicrobial resistance or Candida infection in infected
pancreatic necrosis. Other factors involved might include more
changes in bacterial ecology due to increased general usage
of antibacterial therapy, and increasing use of central venous
catheters for monitoring and parenteral nutrition. In one series
of 46 patients with infected pancreatic necrosis, resistant bacteria
were yielded from 52%, with increasing risk in proportion to
the duration of prophylaxis (De Waele 2004). In a large series
of infected pancreatic necrosis cases published prior to wide
usage of prophylaxis, the predominant infecting organisms were
Escherichia coli and Bacteroides species with an incidence of
Candida infection of only 2.6% (Beger 1986). A study of two
diHerent prophylactic antibacterial regimens found the most
isolated microorganisms in pancreatic necrosis specimens were
methicillin resistant Staphylococcus aureus (MRSA) (8.3%) and
Candida glabrata (6.6%) (Bassi 1998). Another study comparing
14 days of imipenem-cilastatin versus more prolonged therapy
reported an incidence of Candida infection in pancreatic necrosis
of 2%, with remote Candida infection rates of 6.5% aOer 14
days rising to 13% with more prolonged treatment (Maravi-Poma
2003). A furtFher study compared pancreatic necrosis patients
treated before and aOer the introduction of routine prophylaxis,
and indicated a shiO from mainly gram-negative to mostly gram-
positive infection, without significant resistance or fungal infection
(Howard 2002). This has led some investigators to advocate the
inclusions of antifungal prophylaxis for patients with pancreatic
necrosis receiving prophylactic antibiotics (Grewe 1999; De Waele
2003).
A counter argument is that the mere presence of Candida within
pancreatic necrosis may indicate only colonisation. One study
argued that outcome was unaHected if Candida species had been
identified and promptly treated (Gloor 2001), whilst two other
studies suggest the contrary (Gotzinger 2001; Connor 2004).
Clearly it is impossible to continuously sample necrotic areas, and
thus Candida infection may go unrecognised and untreated. The
question of whether Candida colonisation constitutes a suHiciently
serious risk to make a case against antibacterial prophylaxis was
discussed in a journal editorial (O'Reilly 2004), but there are scant
data on which to draw a firm conclusion.
Why it is important to do this review
A previous version of this review published in 2006 (Villatoro
2006) suggested a survival advantage overall, and a decrease in
pancreatic sepsis for the beta-lactam therapy group. Since that
review two further studies have been published: both were double-
blinded, randomised, clinical trials (RCTs) (Dellinger 2007; Røkke
2007). These studies have now been included. The conclusions of
this review have changed as a result of the inclusion of these two
studies.
Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis (Review)
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O B J E C T I V E S
To determine the eHicacy and safety of prophylactic antibiotic
therapy in patients suHering from severe acute pancreatitis proven
to have developed pancreatic necrosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) in which prophylactic
antibiotic therapy was evaluated in severe acute pancreatitis with
proven pancreatic necrosis, in comparison with placebo therapy
and best supportive care.
Types of participants
Patients with severe acute pancreatitis in whom pancreatic
necrosis has been diagnosed by intravenous contrast enhanced CT
according to internationally agreed criteria (Atlanta and Santorini
criteria) (Bradley 1993; Dervenis 1999).
Types of interventions
Antibacterial therapy administered with the intention of preventing
the infection of pancreatic necrosis, commenced within seven days
of onset of the attack. Trials which combined antibacterial therapy
with selective decontamination or other type of intervention were
not be considered.
Types of outcome measures
Primary outcomes
All cause mortality and rates of microbiologically proven infected
pancreatic necrosis (needle aspirate or operative samples)
Secondary outcomes
Rates of microbiologically proven non-pancreatic infection
(respiratory, urinary, central venous line sepsis) from appropriate
samples, overall infection rates (pancreatic and non-pancreatic),
operative rates for debridement of pancreatic necrosis,
opportunistic fungal infections, and reported incidence of
antimicrobial drug resistant infections.
Search methods for identification of studies
Searches were conducted to identify all published and unpublished
randomised controlled trials (RCTs). The search strategy identified
studies in all languages and, when necessary, non English language
papers were translated so that they could be fully assessed for
potential inclusion in the review.
Trials were identified by searching the Cochrane Library (Issue
2 - 2008), MEDLINE (January 1966 - November 2008), EMBASE
(January 1980 - November 2008) and CINAHL (January 1982
- November 2008). This was updated from previous published
reviews. All search strategies (Appendix 1; Appendix 2; Appendix
3) were constructed by using a combination of subject headings
and text words relating to the use of antibiotics for the treatment
of acute pancreatitis. The standard Cochrane search strategy filter
for identifying randomised controlled trials was applied to all
searches.
Reference lists from the trials selected by electronic searching were
hand searched to identify further relevant trials.
The following conference abstracts were hand searched to identify
further potentially relevant studies for inclusion in the review:
• American Hepato-Pancreato-Biliary Association (AHPBA)
• American Pancreatic Association
• Association of Upper GI Surgeons (AUGIS)
• British Society of Gastroenterology
• Digestive Diseases Week
• European Pancreatic Club
• International Association of Pancreatology
• International Hepatobiliary Association
• Pancreas Club Inc.
• Pancreatic Society of Great Britain and Ireland
• United European Gastroenterology Week
• World Congress of Gastroenterology
In addition, colleagues in the field of surgical and medical
gastroenterology were contacted and asked to provide details of
outstanding clinical trials or any relevant unpublished materials.
Data collection and analysis
Selection of studies
All randomised controlled trials which met the inclusion criteria
were retrieved. Two reviewers independently assessed the
exclusion of papers identified from the initial searches which
were unrelated to pancreatic necrosis in humans. These decisions
were based on assessment of at least the title and abstract if
available. Decisions on inclusion were also made independently by
two reviewers according to the pre-stated eligibility criteria, and
recorded on a paper form. It was planned that a third reviewer
should review disagreements, but this proved unnecessary.
Data extraction and management
Data was extracted and recorded onto specially developed forms.
Authors were approached when clarification was required for
unclear or missing data. Extraction of data was undertaken by two
reviewers and checked by a third.
The following characteristics were recorded for each trial: details
of the participants including demographic characteristics, source
of recruitment, and criteria for diagnosis. Adverse events were
noted, especially reports of anti-microbial drug resistance and
opportunistic fungal infections. Data were extracted from intention
to treat analyses if presented.
Reporting
Applicability and cost benefit analysis were considered. Comments
were to be made on non-RCTs, rejected trials and trials in progress
or analysis where appropriate.
Assessment of risk of bias in included studies
Assessment of Study Quality
This was performed by one reviewer and checked by a second.
Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis (Review)
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Trials meeting the eligibility criteria were assessed for quality
according to four characteristics:
• Generation of the allocation schedule: truly random, quasi-
random, systematic, not stated/unclear. Computer generated
random numbers, coin toss, shuHles, etc were defined as truly
random, allocation according to date of birth, patient number,
etc are defined as quasi-random, whilst alternate allocation and
deterministic methods were classified as systematic.
• Concealment of the treatment allocation: adequate,
inadequate, or unclear. If investigators were unaware of each
participant's allocation when they are recruited, the allocation
was considered to be adequately concealed. Methods such as
central randomisation systems or serially numbered opaque
envelopes were judged to fit this criterion. If an investigator
may have been aware of allocations at recruitment, as when the
participant's birth-date or patient number is used for allocation,
the allocation was judged inadequate.
• Implementation of masking: (patients' masked, clinicians'
masked, outcome assessors' masked). When a placebo was
used it was assumed that the participants are masked to their
treatment allocation.
• Completeness of follow-up and intention to treat analysis: drop-
outs and missing data rates by group.
Measures of treatment e<ect
Data was entered into RevMan5 by one reviewer and double
checked by a second reviewer. Meta-analysis was performed with
computation of risk ratios.
Data synthesis
For outcome measures (death or survival, or other selected event
rates), the impact of the intervention was expressed as risk ratios
with 95% confidence intervals. Meta-analysis was only planned to
be attempted if there were suHicient trials of similar comparisons
reporting the same outcomes. The eHect (or lack of eHect) of
therapy was reported as risk ratios with 95% confidence intervals.
Subgroup analysis and investigation of heterogeneity
Subgroup Analyses
The data were analysed as comparisons between antibiotic and
placebo with conservative management when available. The
review protocol originally planned to categorise the data according
to the following pre-specified subgroups:
1. the type of antibiotic regimen (i.e. beta-lactam, such as penicillin
or cephalosporin based, or quinolone plus imidazole);
2. the time of commencement of therapy in relation to symptom
onset and/or hospitalisation, and duration of therapy;
3. aetiology of the attack (attributable to gallstones, alcohol, other
identifiable causes, and idiopathic).
Complete data was only found for the type of antibiotic regimen
for the previous versions of this review, and therefore the other
subgroup analyses have been omitted.
Investigation of heterogeneity
Significant (P<0.1) heterogeneity was detected in several secondary
end-points. As a result possible explanations were investigated
informally, and a random eHect meta-analysis (instead of a fixed-
eHect one as in previous versions of this review) was performed for
all end-points.
R E S U L T S
Description of studies
Results of the search
Since 1975 there have been fourteen reported RCTs which
investigated antibiotic prophylaxis in severe acute pancreatitis.
No additional RCTs with fully evaluable data were identified from
unpublished data sources.
Included studies
Please see the 'Characteristics of included studies' table for full
details. The seven included studies were those published by
Pederzoli 1993; Sainio 1995; Nordback 2001; Schwarz 1997 (aOer
translation from German to English by a qualified bi-lingual medical
practitioner; Isenmann 2004; Røkke 2007; Dellinger 2007. Two
further RCTs have been presented in abstract form and published
in Czech language (Spicak 2002; Spicak 2003), but no subgroup of
participants with CT proven necrosis has been identified. A further
study from the same author has been published in abstract form
(Spicak 2004), appears to include from the two previous studies
cases in a subgroup of participants with pancreatic necrosis,
therefore a decision was taken to await full publication.
Design
All of the included studies were randomised controlled trials.
Sample sizes
These seven studies randomised a total of 404 participants with
proven pancreatic necrosis, 203 to an antibacterial regimen and 201
to control.
Setting
The study reported by Røkke (Røkke 2007) was a multicentre,
randomised controlled trial conducted in seven hospitals in
Norway. The study reported by Dellinger (Dellinger 2007) was
an international, multicentre, randomised, placebo-controlled
double-blind trial, (carried out in centres from the USA, Belgium,
Germany, Spain, and the UK)and evaluated meropenem (a beta-
lactam) as the study drug. Isenmann 2004 included centres across
Germany in Ulm, Essen, Magdeburg, Nuremberg, and Heidenheim.
The randomised controlled trial from Tampere, Finland, was
reported by Nordback 2001; Sainio 1995 was also carried out in
Finland (Helsinki). Pederzoli 1993 included six centres in Italy.
The non-blinded randomised controlled trial reported by Schwarz
(Schwarz 1997) was conducted at Ulm University Surgical Clinic, in
Germany.
Participants
In Pederzoli 1993 a total of 74 participants with severe acute
pancreatitis and pancreatic necrosis confirmed on CT were studied
between January 1989 and July 1991.
In Sainio 1995 a total of 60 participants were recruited with severe
alcohol associated acute pancreatitis, raised C-reactive protein
(CRP) of 120mg/L or above and pancreatic necrosis proven by CT.
The study ran between July 1989 and November 1993.
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In Schwarz 1997, twenty six participants were defined as having
severe acute pancreatitis, using CT criteria, from August 1991 to
October 1994.
Nordback 2001 reported that researchers recruited a total of 58
participants with acute pancreatitis with both pancreatic necrosis
on CT and CRP of 150mg/L or above during the first 24 hours post-
admission to Hospital from September 1995 to May 1999.
The study reported by Isenmann 2004 was originally designed to
recruit a sample size of 200 participants so that it would achieve
a 90% power (β) to detect a halving of the infection rate from 40
to 20%. AOer 114 participants were recruited, an interim analysis
was performed and recruitment stopped, as the trend in end-
point events ran in the opposite direction of that expected. The
study assessed participants within 72 hours of onset of symptoms,
and a minimum of a 3-fold elevation of serum amylase or lipase.
participants were included if a severe attack was predicted from a
CRP exceeding 150mg/L, or the presence of pancreatic necrosis on
CT criteria. The study inclusion criteria attracted criticism (Brown
2004) because, as with the study of Sainio (Sainio 1995), CRP was
used for stratification. Brown noted that there is no internationally
accepted criterion level or time point for CRP stratification, and
it was not included in the Atlanta Classification (Bradley 1993).
However as with the study of Sainio, data were easily extracted
on participants meeting CT criteria for the diagnosis of pancreatic
necrosis for the purposes of the present review.
The study reported by Dellinger (Dellinger 2007) recruited 100
participants, of which 82 had CT proven necrosis at the time
of inclusion. Of this subgroup 41 were randomised to treatment
and 41 to placebo. A decision was taken to cease recruitment
due to funding restrictions, despite a prior calculation that
240 participants were required (120 per group), to ensure
adequate power. The primary end-point of the study was to
evaluate the eHectiveness of prophylactic intravenous meropenem
in decreasing the incidence of pancreatic or peripancreatic
infection in participants with necrotising pancreatitis, within 42
days following randomisation. Secondary end-points were time
between onset of pancreatitis and the development of pancreatic
or peripancreatic infection, all-cause mortality, requirement
for surgical intervention, and development of non-pancreatic
infections within 42 days following randomisation. In order to do
that, the investigators searched for participants with proven CT
necrosis or, for those participants on which it was not possible to
use intravenous contrast due to renal impairment, with CT findings
of Balthazar grade E (multiple peripancreatic fluid collections and
pancreatic oedema) and either a CRP level of more than 120 mg/L
or a multiple organ dysfunction (MOD) score of more than 2.
In Røkke 2007 A total of 73 participants with symptoms of less than
72 hours duration were recruited. A power calculation estimated
that a total of 160 participants would be needed to provide 80%
power (β) to demonstrate a halving of infectious complications,
from 50 to 25%. Due to slow recruitment the study was closed prior
to this total being reached. Inclusion was based on a CRP rising
above 120mg/l within the first 24 hours, or above 200mg/l within 48
hours, or pancreatic necrosis demonstrated on CT.
Interventions
Five studies (Dellinger 2007; Nordback 2001; Pederzoli 1993;
Sainio 1995; Røkke 2007) evaluated a beta-lactam regimen in 302
participants (149 treatment, 153 controls), and two (Isenmann
2004; Schwarz 1997) a quinolone plus imidazole regimen in 102
participants (54 treatment, 48 controls).
Pederzoli 1993 allocated forty one participants (mean age 54
years) to the treatment group who received intravenous imipenem/
cilastatin (500mg every eight hours) for 14 days from the
time of diagnosis of pancreatic necrosis at CT. Another 33
participants (mean age 50 years) were allocated to the control
group. All participants received standard medical (conservative)
therapy (nasogastric suction, H2-blockers, antiprotease drugs, total
parenteral nutrition and analgesics).
Thirty of the 60 participants in Sainio 1995 (mean age 43
years) received supportive medical treatment and intravenous
1.5g cefuroxime every 8 hours from admission until clinical
recovery and normal CRP concentration were achieved; in cases
of clinical recovery but moderately raised CRP concentration, oral
cefuroxime 250mg orally 12 hourly was continued for 14 days. The
other 30 participants (mean age 38.7 years) received supportive
medical treatment, with antibiotics started only when clinically,
microbiologically or radiologically indicated, or when there was a
secondary rise in the CRP exceeding 20% aOer the peak acute phase
level.
Thirteen of the 26 participants (mean age 43 years) in Schwarz
1997 received supportive medical treatment plus 200mg ofloxacin
and 500mg metronidazole twice daily for 10 days. The other 13
participants (mean age 46 years) received supportive medical
treatment adding antibiotics only when clinically indicated, or
if evidence of infection of the necrotic pancreatic tissue was
obtained.
in Nordback 2001 twenty five of fiOy eight participants (mean age
47 years) received supportive treatment and 1g imipenem with
cilastatin intravenously every 8 hours. The point of cessation of
prophylactic antibiotics was not defined. A further 33 participants
(mean age 46 years) received only supportive treatment. Imipenem
with cilastatin was also administered to 14 control participants
in whom it was clinically indicated due to consistent increases
in inflammatory markers, or aOer bacteriology positive CT or
ultrasonographically guided fine needle aspirate (FNA) from
necrotic areas. Nine of those 14 participants responded and
avoided the need for surgery, with only 5 participants requiring
surgical debridement, which was carried out a minimum of 3 days
later.
In Isenmann 2004 participants were randomised to receive 400mg
ciprofloxacin and 500 mg metronidazole intravenously twice daily,
or placebo. Study medication was intended to continue for up to
21 days. Of the 114 participants included, 76 were found to have
pancreatic necrosis at CT, of which 41 (median age 49.4) received
prophylactic antibiotics and 35 (median age 46.5) were controls.
Only participants with pancreatic necrosis are included in this
review. The study medication was discontinued before day 21 if
the participant recovered, or switched to open antibiotics following
an operational rule that participants were transferred from blinded
treatment to 'open' antibiotic treatment if they continued to
deteriorate. This crossover policy reflects clinical practice, but
reduces the previously calculated study power. In the subgroup
with pancreatic necrosis, 35 of the 76 participants received
crossover 'open' antibiotics, which included15 participants of 41 in
Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis (Review)
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the antibiotic group (35.6%), and 20 from 35 in the control group
(57.1%).
FiOy participants in each group (intervention and control) reported
in Dellinger 2007 were randomised to receive intravenously either
1g meropenem or placebo every 8 hours. For participants to be
included the study it was required that treatment (meropenem
or placebo) was commenced within 120 hours of the onset of
symptoms. The published study did not include separate data on
the subgroup of participants in whom necrosis was detected in CT
scanning, except for the endpoint of pancreatic or peripancreatic
infection, but this information was kindly provided by Professor
Dellinger. This subgroup consisted of 82 patients with CT proven
necrosis at the time of inclusion, with 41 receiving antibiotic
prophylaxis and 41 placebo. We do not have the mean ages for
patients in either arms of this subgroup. They excluded participants
who at time of randomisation were diagnosed with pancreatic or
peripancreatic infection, or had a course of antibiotics for more
than 48 hours prior to randomisation, or who had an allergy to beta-
lactams. Other exclusions included probenecid use, underlying
progressing disease and pregnancy.
In Røkke 2007 A total of 73 participants with symptoms of less than
72 hours duration were recruited. Participants were randomised
to receive intravenously either 500mg Imipenem or placebo thrice
daily. Participants in either group received antibiotics if infection
was diagnosed on clinical, radiological or laboratory criteria. CT
or ultrasonographic scan (USS) guided fine-needle aspiration and
bacteriological analysis was not routinely employed. Dr Røkke
provided unpublished data on 28 participants with CT confirmed
necrosis, of which 12 were randomised to imipenem group and 16
to placebo. We do not have the mean ages for patients on either arm
of this subgroup.
Outcomes
Pederzoli 1993 reported a statistically significant decrease in the
incidence of infection of pancreatic necrosis (12.2% versus 30.3%)
and of non-pancreatic infections (14.6% versus 48.5%), but there
were no significant diHerences in mortality (7.3% versus 12.1%),
incidence of MOSF (29.3% versus 39.4%), or number of operations
performed (29.3% versus 33.3%).
In Sainio 1995 mortality was significantly lower in the treated
group, with 1 death in this group (3.3%) versus 7 in the
placebo group (23.3%). It is important to note that two of the
deaths that occurred in the control group happened at 2 and
4 days from diagnosis, making it unlikely that infection of the
pancreatic necrosis was causal (Beger 1986), although the authors
argued that sepsis may have worsened the pre-existing MOSF.
The authors concluded that given the low cost and apparent
advantages of antibiotic treatment, with an apparent reduction in
mortality possibly due to a decrease in the frequency of sepsis,
such treatment should be started early in all participants with
necrotising pancreatitis.
There was an steady improvement in the clinical condition in the
treated group in Schwarz 1997 as demonstrated by a fall in their
APACHE II scores from day 1 to day 10 (means of 15 at day 1 and
9.5 at day 10), whereas the APACHE II scores calculated for the
placebo group showed a steady increase in the same time period
(means of 11.5 at day 1 and 16 at day 10). This was statistically
significant (Wilcoxon test, P<0.01). None of the participants in the
antibiotic group died within the first three weeks, whereas there
were 2 deaths in the control group for the same time period. The
authors concluded that antibiotic prophylaxis neither prevented
nor delayed bacterial infection of the necrotic pancreas, but that
antibiotic therapy improved the clinical course when commenced
before the onset of clinically obvious infection of the pancreatic
necrosis.
The study investigators in Nordback 2001 concluded that, although
their findings were not statistically significant, prophylaxis using
imipenem with cilastatin therapy appeared to reduce mortality (8%
versus 15%), need for surgery (8% versus 36%), and the overall
number of major organ complications (28% versus 76%).
The investigators in Isenmann 2004 concluded that no benefit
was shown for the use of antibiotic prophylaxis against infection
of pancreatic necrosis complicating acute pancreatitis. Given the
large number of participants in the antibiotic group who had the
initial antibiotics changed, and the large number of patients in
the control group that were switched to antibiotic treatment, a
bias against treatment benefit could have been introduced, which
would have reduced the calculated power of the study (Brown
2004).
The results of Dellinger 2007 did not show a statistical diHerence
between groups of any of the end-points: development of
pancreatic or peripancreatic infection (19.5% treatment versus
12.2% placebo), mortality (14.6% treatment versus 12.2% placebo),
non-pancreatic infection (31.7% treatment versus 41.5% placebo),
or need for surgical intervention (24.4% treatment versus 17.1%
placebo). The investigators concluded that this study did not
have suHicient power to reject benefit from the use of antibiotic
prophylaxis, but argued that when evaluated alongside previous
studies the routine adoption of this measure was not justified.
Professor Dellinger provided further information on the 82
participants with CT diagnosed necrosis, which included 41
receiving antibiotic prophylaxis and 41 receiving placebo. Only
this subgroup was entered into the present meta-analysis. Most
participants received nutritional support, and there was no
significant diHerence in provision between the treatment and the
placebo groups.
As stated before, unpublished data provided by Dr Røkke allowed
us to identify the 28 participants from his study (Røkke 2007)
with CT confirmed necrosis, which included 12 randomised to
imipenem group and 16 to placebo. Only this CT confirmed
necrosis subgroup is included in this meta-analysis. No statistically
significant diHerence between the groups was found for mortality
(16.6% treatment versus 12.5% controls), organ failure (data for
subgroup with CT proven necrosis not available), or rates of
intervention (16.6% treatment versus 12.5% controls). There was
however a statistically significant reduction in complications rates
and for pancreatic and extrapancreatic infections. There appeared
to be a delay in the onset of infection in participants receiving
antibiotics, in that no infections were evident before the third week
aOer onset in this group.
Excluded studies
The three earliest studies were published in the 1970s, and were
excluded as at the time CT was not available for the diagnosis of
pancreatic necrosis (Finch 1976; Howes 1975; Craig 1975). Of the
eleven remaining studies, two further examples were excluded as
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they did not comply with study criteria (Luiten 1995 and Delcenserie
1996). Luiten's study assessed the role of antibacterial prophylaxis
combined with selective gastrointestinal tract decontamination.
Also, both in this and Delcenserie's studies, participants were
selected because they had fluid collections on CT rather than
pancreatic necrosis, making them unsuitable for inclusion in this
review as CT data confirming pancreatic necrosis could not be
extracted. Please see the 'Characteristics of excluded studies' table.
Risk of bias in included studies
Please see Figure 1 for a summary of the risk of bias in the included
studies.
 
Figure 1.   Methodological quality summary: review authors' judgements about each methodological quality item
for each included study.
 
Allocation
In Pederzoli 1993 and Sainio 1995 the method of randomisation
was by casual number table (pre-printed random tables). In
Schwarz 1997 and Nordback 2001 the method of randomisation
was not stated. Isenmann 2004 randomised by consecutive patient
numbers. Røkke 2007 and Dellinger 2007 used computer-based
randomisation (without stratification for participating centres in
Røkke 2007).
Allocation concealment was adequate in all the trials except
Nordback 2001 where allocation concealment was unclear and
Røkke 2007 where allocation was inadequate.
The groups were comparable in all the included studies.
Blinding
Only two studies were double blind; Isenmann 2004 and Dellinger
2007.
Incomplete outcome data
Outcome data were fully reported in all the included studies. In
Pederzoli 1993 there was complete follow-up until death or hospital
discharge; in Isenmann 2004 there was complete follow-up until
death or hospital discharge. In Røkke 2007 no participants were lost
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or excluded from the analysis, and follow-up in Dellinger 2007 until
death or a minimum of 42 days was reported.
E<ects of interventions
The eHects of interventions for all studies are detailed below. Sub-
group analyses were performed for the type of antibiotic regimen:
beta-lactam regimen in 302 participants (149 in treatment and
153 in control groups) (Dellinger 2007; Nordback 2001; Pederzoli
1993; Sainio 1995; Røkke 2007), and a quinolone plus imidazole
regimen in 102 participants (54 in treatment and 48 in control
groups) (Isenmann 2004; Schwarz 1997). Sub-group analyses could
only be performed if data were available for at least two studies
in each group. Since there now were 3 studies using the same
antibiotic (imipenem), a sub-group analysis for imipenem was also
performed including 160 participants (78 in treatment and 82 in
control groups).
1.Antibiotics versus control
Participants within the studies were of comparable age and gender.
Aetiological variations were as expected and in keeping with known
geographical and cultural diHerences.
Mortality
All cause mortality was evaluable in all seven included studies.
Antibacterial prophylaxis was associated a decrease in mortality
(8.4%) versus controls (14.4%), but this was not significant (P=0.07;
RR 0.60, 95% CI 0.34 to 1.05) (Analysis 1.1). Most of the survival
advantage was contributed by the study of Sainio 1995 (weight
23.9%).
Infected pancreatic necrosis
Infected pancreatic necrosis was not significantly diHerent between
treatment and placebo groups. Infection occurred in 40 out of 203
participants treated with antibiotics (19.7%), versus 49 out of 201
controls (24.4%) (P=0.42; RR 0.85, 95% CI 0.57 to 1.26) (Analysis 1.2),
with Schwarz 1997 contributing most weight at 26.5%.
Non-pancreatic infections
Non-pancreatic infection was not evaluable in Sainio 1995 as
'infective events' rather than individual participants aHected were
reported. Non-pancreatic infections were not reported at all in
Schwarz 1997. Therefore these two studies could not be included
in the analysis of non-pancreatic infection. In the remaining five
studies, there were less episodes in antibiotic treated participants
(38 of 160, 23.7%) versus controls (57 of 158, 36%), but this
diHerence was not statistically significant (P=0.08; RR 0.62, 95% CI
0.36 to 1.06) (Analysis 1.3).
All sites infections
As the incidence of non-pancreatic infections could not be
evaluated in either the Sainio 1995 or the Schwarz 1997 studies,
they were not included in the analysis of all site infections, that
is, the total incidence of both pancreatic and non-pancreatic
infections. All sites infection episodes were less common in the
antibiotic group (60 out of 160, 37.5%) than in controls (82 out
of 158, 51.9%), but this diHerence was not statistically significant
(P=0.12; RR 0.69, 95% CI 0.44 to 1.09) (Analysis 1.4).
Resistant organisms
Only Isenmann 2004 and Dellinger 2007 reported on infection
with resistant organisms. In Isenmann 2004, the authors reported
a significant increase of infection by ciprofloxacin resistant
organisms in the antibiotic group, ciprofloxacin being the
antibacterial agent used in this study (P<0.0001). In Dellinger 2007
there were 5 bacterial isolates resistant to meropenem in the
treatment group (4 pancreatic and 1 non-pancreatic infections),
and 5 in controls (2 pancreatic and 3 non-pancreatic infections).
Neither study provided details as to whether isolates belonged to
individual participants, or which organisms were cultured.
Fungal infections
Fungal infections were evaluable in all studies, and were not
significantly increased in the antibiotic treated group, with an
incidence of 8 out of 203 (3.9%) treated participants versus 10 out
of 201 controls (5%) (P=0.91; RR 1.06, 95% CI 0.41 to 2.70) (Analysis
1.5). Schwarz 1997 contributed most weight at 33.9%.
Operative treatment
Operative treatment rates were unavailable for the study of
Schwarz 1997. In the remaining six studies there were no significant
diHerences between participants treated with antibiotics (43 of 190,
22.6%) versus controls (45 of 188, 24%) (P=0.58; RR 0.90, 95% CI 0.62
to 1.31) (Analysis 1.6).
2. Beta-lactam versus control
Mortality
In studies using beta-lactam prophylaxis, treatment was associated
with fewer deaths at 9.4% versus controls 15%, but this was
not statistically significant (P=0.33; RR 0.72, 95% CI 0.37 to 1.40)
(Analysis 2.1).
Infected pancreatic necrosis
Rates of infection of pancreatic necrosis were less frequent, but not
significantly so, with treatment at 16.8% versus 24.2% in controls
(P=0.19; RR 0.69, 95% CI 0.40 to 1.19) (Analysis 2.2).
Non-pancreatic infections
There was a non-significant trend towards lower incidence of
non-pancreatic infections of 21% in the treatment group, versus
32.5% in the control group (P=0.29; RR 0.64, 95% CI 0.28 to
1.47) (Analysis 2.3); but this endpoint included only four studies
(Dellinger 2007; Pederzoli 1993; Nordback 2001; Røkke 2007), as
Sainio's study (Sainio 1995) reported infective events rather than
individual participants aHected, as mentioned earlier.
All sites infections
Overall infections were non-significantly lower in this subgroup
with an incidence of 34.4% in those treated versus 52.8% in the
control group (P=0.12; RR 0.63; 95% CI 0.35 to 1.13) (Analysis 2.4),
and this included the same four studies as described for non-
pancreatic infections (Pederzoli 1993; Nordback 2001; Røkke 2007;
Dellinger 2007).
Fungal infections and operative rates
There were no significant diHerences in operative rates or fungal
infection rates (Analysis 2.5; Analysis 2.6).
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3. Quinolone versus control
Mortality
In studies of quinolone plus imidazole prophylaxis, there was no
significant diHerence in mortality at 5.5% with treatment versus
12.5% in controls (P=0.31; RR 0.51, 95% CI 0.14 to 1.85) (Analysis
3.1).
Infected pancreatic necrosis
Rates of pancreatic sepsis were not significantly diHerent between
treatment groups at 27.8% versus 25% in controls (P=0.61; RR 1.16,
95% CI 0.66 to 2.03) (Analysis 3.2).
Non-pancreatic infections and all sites infections
Only one study (Isenmann 2004) reported on extra-pancreatic
infections, with Schwarz 1997 reporting on infective events instead,
and therefore a subgroup analysis could not be performed in either
this category or in overall pancreatic infections.
Fungal infections
There was no significant diHerence in fungal infection rates, at 7.4%
for treatment versus 6.2% in controls (P=0.71; RR 1.30, 95% CI 0.32
to 5.21) (Analysis 3.3).
Operative treatment
Operation rates were only available in one study (Isenmann 2004)
(data not shown).
4. Imipenem versus control
Mortality
Although not originally planned as a formal sub-group analysis,
it was noted that when the studies evaluating imipenem plus
cilastatin versus control (Pederzoli 1993; Nordback 2001; Røkke
2007) are considered separately, there was no significant reduction
of mortality associated with treatment (9%) versus control (13.4%)
(P=0.45; RR 0.70, 95% CI 0.28 to 1.75) (Analysis 4.1),
Infected pancreatic necrosis
There were significant reductions in rates of infection of pancreatic
necrosis (10.2% versus 24.4%) (P=0.02; RR 0.34, 95% CI 0.13 to 0.84)
(Analysis 4.2)
Non-pancreatic infections and all sites infections
There were significant reductions in rates of infections overall
(25.6% versus 52.4%) (P=0.01; RR 0.49; 95% CI 0.28 to 0.87) (Analysis
4.4), but in this subgroup there were no significant diHerences in
rates of non-pancreatic infections (15.4% versus 28%) (P=0.58; RR
0.67, 95% CI 0.16 to 2.77; Analysis 4.3)
Fungal infections and operative treatment
There were no significant diHerences in rates of fungal infection
(Analysis 4.5) or rates of operation (Analysis 4.6) in each group.
5. Other analyses
Other sub-group analyses planned in the protocol, but not
performed include:
1. the time of commencement of therapy in relation to symptom
onset and hospitalisation, and duration of therapy. This was
due to lack of reported data on commencement and variability
in duration of treatment. One study (Røkke 2007) employed
antibiotic prophylaxis for 5 to 7 days, another (Schwarz
1997) adopted a treatment duration of 10 days, with another
(Isenmann 2004) study permitting up to 21 days therapy.
The four remaining studies (Dellinger 2007; Nordback 2001;
Pederzoli 1993; Sainio 1995; ) set a treatment duration of 14
days, but with varying stopping criteria;
2. aetiology of the attack: a sub-analysis for attacks attributed to
gallstones, alcohol, other identifiable causes, and idiopathic was
planned. Although data were provided for aetiology of the whole
study group at inclusion, no study provided suHicient data to
enable outcomes to be analysed by aetiology.
D I S C U S S I O N
Summary of main results
A previous version of this review published in 2006 (Villatoro
2006) which evaluated 5 studies, compared with 7 in the current
review, suggested a significant survival advantage for the antibiotic
treated group. In addition, within the subgroup treated with
a beta-lactam, also significantly decreased rates for infection
of pancreatic necrosis, in contrast to quinolone plus imidazole
regimens with were not associated with any significant diHerences
in outcome. Since that review two further RCTs, one double-blinded
(Dellinger 2007) and the other unblinded (Røkke 2007), have
been published and met the criteria for inclusion. Following the
addition of these two RCTs, although there remains a trend towards
lower mortality aOer antibiotic therapy, meta-analysis no longer
demonstrates the significant survival advantage demonstrated
in the previous version of this review (Villatoro 2006). However,
there are significantly lower rates for non-pancreatic infections.
There were also persisting trends towards decreased rates of
pancreatic infection and operative debridement associated with
antibiotic treatment, but there were no significant diHerences.
Although the hypothesis underpinning each RCT was that antibiotic
prophylaxis could prevent pancreatic infection, it appears possible
that any positive treatment eHect may be an eHect of reduced rates
of non-pancreatic sepsis, such as serious pulmonary infections.
Røkke (Røkke 2007) postulated that reducing the risk of serious
non-pancreatic infection might beneficially delay the onset of
pancreatic infection. However there was some heterogeneity
between RCTs in the analysis of non-pancreatic infections, and
this may be a result of the lack of classification of non-pancreatic
infections specified within the Atlanta (Bradley 1993) or Santorini
(Dervenis 1999) criteria. Data for antimicrobial resistance were only
available from two studies (Dellinger 2007; Isenmann 2004), and
none of the seven studies provided data concerning aetiology in
relation to outcome. There was no significant diHerence in the rates
of fungal infection between groups, although the overall incidence
was low at 4.5%, compared with published reports (Grewe 1999;
Gloor 2001; De Waele 2003). Fungal infections are more diHicult to
detect than bacterial infections. Sub-group analyses suggested that
diHerent treatment regimens may provide diHerent results: beta-
lactam treatment appears to produce a greater treatment eHect
than quinolone/imidazole combinations. The reduced numbers of
participants in the sub-group analyses may mask other genuine
diHerential treatment eHects.
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Overall completeness and applicability of evidence
The results of the present review show only a trend towards
improved survival and infection rates for pancreatic necrosis aOer
antibiotic prophylaxis, but there was significant reduction of non-
pancreatic infection. This may be explained due to a therapeutic
eHect on, for example, serious pulmonary infections, with are
relatively common secondary events in patients with severe acute
pancreatitis and acute respiratory distress syndrome. However this
view is not supported by data, as specific infections were not
detailed in any of the studies reviewed.
Examining subgroups receiving prophylaxis with a beta-lactam (
Dellinger 2007; Nordback 2001; Pederzoli 1993; Sainio 1995; Røkke
2007) versus quinolone and imidazole combinations (Isenmann
2004; Schwarz 1997), significantly decreased non-pancreatic
infection was confirmed for the former but not the latter, where
the trend reversed towards worsened survival. When evaluating
all sites infection, that is, both pancreatic and non-pancreatic
infections, the beta-lactam subgroup retains a significant reduction
of infection, but such analysis could not be done in the quinolone
and imidazole combination group since only data from one study
was available for analysis (Isenmann 2004).
It is diHicult to conduct a cost benefit analysis for the prophylaxis
of superinfection in pancreatic necrosis, as the costs of the drugs
vary, as does the cost provision of critical care therapy and surgery.
The UK National Health Service Economic Evaluation Database
(NHS EED, Cochrane Library) identifies four studies in which the
title suggested that cost-eHectiveness was covered, but none were
abstracted as they covered only costs rather than balancing these
with the eHect of benefits. A study of patients operated upon in the
early 1990s for infected pancreatic necrosis in Glasgow, Scotland,
estimated an average cost at £18,441 with a range extending up
to £34,000 (Fenton-Lee 1993). The management of patients with
infected necrosis oOen requires repeated visits to the operating
theatre, multiple CT scans, and weeks or months in critical care
areas. There appeared to be no significant reduction in operative
rates despite reduced superinfection and mortality rates - a factor
which suggests a need for larger studies or more strict management
protocols. Røkke's study (Røkke 2007) warned that the reduction of
septic episodes and delayed onset of infection of necrosis observed
in the treatment arm of his RCT came at a cost double that of the
control group, which was not felt to be cost eHective as there was no
significantly decreased mortality nor surgical interventions rates.
Representative, contemporary costs of treatment regimes in the
UK were analysed using the 57th edition of the British National
Formulary (http://www.bnf.org.uk). The most expensive agent
evaluated in the present review was meropenem (Dellinger 2007)
which at 1g thrice daily costs £85.95 per day, followed by imipenem
with cilastatin (Nordback 2001) which at 1g thrice daily costs
£72 per day, ciprofloxacin 400mg and metronidazole 500mg
twice daily (Isenmann 2004) at £50.82p daily (ciprofloxacin £44,
metronidazole £6.82p), then ofloxacin 200mg plus metronidazole
500mg twice daily (Schwarz 1997) at £40.46p daily (ofloxacin
£33.64p, metronidazole £6.82p), imipenem with cilastatin at 500mg
three times a day (Pederzoli 1993; Røkke 2007) at £36 per day,
with the least expensive regimen being cefuroxime 1.5g three times
a day (Sainio 1995) at £14.10 per day, costing 16% of the most
expensive.
Quality of the evidence
A major concern over the quality of design and execution of
the RCTs reviewed remains. However they extend over a long
time period, and whilst earlier studies reflected a state of the art
approach at the time they were conducted, it is only relatively
recently that two double-blinded studies have been carried out.
Any future studies would now be expected to follow this approach.
Although it is accepted that there are diHiculties in meeting
predicted sample sizes, future studies should be properly resourced
so that funding restraints do not play a part in decisions to cease a
study on the basis of interim results (Werner 2007).
Potential biases in the review process
None known.
Agreements and disagreements with other studies or
reviews
A previous meta-analysis examined eight prospective RCTs of
antibiotic prophylaxis in acute pancreatitis (Golub 1998), but
studies were not selected on the basis of inclusion with pancreatic
necrosis proven on CT, and mortality was the only end-point
analysed. A large variety of sub-analyses involving diHerent
combinations of studies was carried out, including one focussing
on four studies evaluating broad spectrum antibiotics (Delcenserie
1996; Pederzoli 1993; Sainio 1995; Schwarz 1997). This subgroup
was associated with significantly reduced mortality in antibiotic
treated patients (5.3%) compared to controls (18.2%), odds ratio
0.25 (95% CI 0.09, 0.72). The authors concluded that patients
with severe pancreatitis by an Imrie or Ranson score of 3 and
above, or apparently severe disease at CT, should receive broad-
spectrum antibiotics such as imipenem or a fluoroquinolone.
However this review did not include the four more recent studies
reviewed here (Dellinger 2007; Isenmann 2004; Nordback 2001;
Røkke 2007) of higher quality, since they were published later.
DARE-CRD reviewers (CRD database: DARE-994541) commented
on the variable methodological quality of this meta-analysis, and
cautioned that the conclusions should be interpreted cautiously
due to the small number of studies included.
A similar review of antibiotic eHectiveness in acute pancreatitis
published in 1999 (Kramer 1999) adopted a diagnostic amylase
level for inclusion rather than using the Atlanta criteria. This
review excluded three studies conducted before CT had become
available for the diagnosis of pancreatic necrosis, but included
one retrospective review. The authors concluded that antibiotics
should be administered to patients with severe disease predicted
by a Ranson score of 3 or above, and two or more acute
fluid collections or necrosis involving one third or more of the
pancreas at CT. However, the review was a narrative and no formal
meta-analysis was performed. DARE-CRD reviewers (CRD database
number: DARE-991015) commented that the aim was not clearly
stated, inclusion criteria were broad, studies were restricted to
those published in English, and conclusions were not strongly
supported by the evidence presented. Again, this review did not
include four later studies analysed in the present review (Dellinger
2007; Nordback 2001; Isenmann 2004; Røkke 2007).
Three further reviews have been published since the last edition of
the present review (Heinrich 2006; Mazaki 2006; De Vries 2007).
Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis (Review)









Cochrane Database of Systematic Reviews
Heinrich's review (Heinrich 2006) focused on evidence-based
management of acute pancreatitis in general. In the analysis
of antibiotic prophylaxis, five studies (Isenmann 2004; Nordback
2001; Pederzoli 1993; Sainio 1995; Schwarz 1997) were considered,
identical to those in the previous version of the present review.
Additional data was provided for the subgroup of patients with
pancreatic necrosis shown by CT in Isenmann's study aOer personal
communication with the authors. However the data analysed
appeared to diHer markedly from that published in the number of
patients with proven necrosis in the treatment and control groups,
perhaps because they included those found to have necrosis both
at operation and CT. The authors decided to exclude this study
(Isenmann 2004) from the mortality analysis, claiming that this
study lacked uniformity in the treatment of infected necrosis.
Their recommendation was that antibiotic prophylaxis should
be routinely adopted for pancreatic necrosis, but this may be
skewed by the exclusion of Isenmann's study. The management of
pancreatic necrosis in Isenmann's study reflected the diversity of
clinical practice, and there was at the time, as now, no rigid protocol
available.
A meta-analysis published by Mazaki 2006 included the same
studies (Isenmann 2004; Nordback 2001; Pederzoli 1993; Sainio
1995; Schwarz 1997) as the review of Heinrich 2006, and the
previous version of the current review (Villatoro 2006), with the
addition of a further study (Spicak 2004). The additional study
was published only in abstract form and appears to contain a
mix of patients from two previously published studies (Spicak
2002; Spicak 2003). As previously mentioned, in the absence of
a full publication and a lack of response to enquiries for data
clarification, the study was excluded from the present review. The
conclusion reached by the authors was that antibiotic prophylaxis
was not associated with significant diHerences in mortality, rates
of infected necrosis, or non-pancreatic infection, but antibiotic
therapy was associated with a significantly reduced length of
hospitalisation in the antibiotic group compared to controls (I-V
fixed weighted mean diHerence, -5.64; 95% CI, -11.0 to -0.27; P
=0.04), but they could only extract this data from three of the six
studies included (Nordback 2001; Sainio 1995; Spicak 2004).
One further review (De Vries 2007) included only studies that
reached a methodological quality threshold from a set of non-
validated criteria which assessed the study population, type of
intervention, and the participant flow. This led to the exclusion
of both Spicak's earlier published studies (Spicak 2002; Spicak
2003). They also excluded Nordback 2001, because they judged
that antibiotic prophylaxis was used in both arms of the study.
In fact, Nordback's study adopted the same approach as other
studies in that ethically, antibiotics could not be withheld once
clinically indicated. The target group for this analysis was severe
acute pancreatitis rather than CT proven necrosis, thus Delcenserie
1996 was included because of the presence of collections at
CT rather than pancreatic necrosis, as were raw published data
from Isenmann's and Dellinger's studies (Isenmann 2004; Dellinger
2007), rather than restricting extraction to patients with proven
necrosis at CT. Accordingly the authors concluded that antibiotic
prophylaxis in severe acute pancreatitis does not prevent deaths or
infection of pancreatic necrosis. As not every patient with severe
acute pancreatitis suHers from pancreatic necrosis, the conclusion
is inappropriate in determining whether antibiotic prophylaxis
prevents infection of confirmed pancreatic necrosis.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This meta-analysis assessed the eHicacy of antibiotic prophylaxis
against infection within a population of subjects proven to be
suHering from established pancreatic necrosis. The inclusion of
patients with severe acute pancreatitis, many of whom would
not be harbouring pancreatic necrosis would have reduced the
potential to confirm therapeutic benefit. The addition of greater
numbers of patients from a further two RCTs has led to an alteration
of the conclusions from the previously published version of this
review (Villatoro 2006). Although there remains a trend towards
increased survival and reduced rates of infection of pancreatic
necrosis, this is no longer statistically significant. Secondary
endpoints also show a trend towards less incidence of non-
pancreatic infections and all sites infections, perhaps conferring a
non-statistically significant tilt in the balance towards a protective
eHect in this group of severely unwell patients. One study was
interpreted by its authors as suggesting a beneficial delay in the
onset of infection, such as to occur aOer the first inflammatory
phase of the attack, thus lessening its eHect and making any
surgical intervention safer since the necrosis would have had time
to mature (Røkke 2007); unfortunately no other study provided data
to support such a concept.
Although a variety of antibacterial agents and regimens were
utilised in the studies evaluated, they are classified in two main
groups. From subgroup analysis it appears that beta-lactam agents,
particularly imipenem, rather than quinolone plus imidazole
combinations were most likely to provide therapeutic benefit,
although it should be stressed that there was no significant
reduction in mortality or rates of infection for the beta-lactam
group as a whole, but only a significant reduction of infection of
the necrosis for the imipenem group. If further studies were to be
undertaken, then a beta-lactam based regimen would appear to be
the most appropriate choice.
Despite widely held misgivings by clinicians about adverse eHects,
no significant risk of adverse eHects from antibiotic prophylaxis
was detected, although data on resistance to routinely available
antibacterial agents was restricted to only two studies (Dellinger
2007; Isenmann 2004). The low reported incidence of fungal
infection requires further investigation, as it is at variance with that
reported in other published studies (Grewe 1999; Gloor 2001; De
Waele 2003).
Available guidelines are vague on the role of antibiotic prophylaxis
in this setting, reflecting the quality of the underlying evidence.
Current UK guidelines (Johnson 2005), suggest that if prophylactic
antibiotics are used these should be continued for a duration of 7 to
14 days, considering local prescribing costs. In the present review
the RCTs included varied too widely with respect to treatment
duration and treatment cessation rules for any meaningful analysis
to be undertaken.
An important message from the current review is that, to achieve
the maximum probability of demonstrating a therapeutic eHect,
studies should be restricted wholly to patients in who pancreatic
necrosis has been proven by CT criteria. CT is now widely available
and can be carried out early in the admission, when it is unusual
for acute renal failure to be so established as to contraindicate
intravenous contrast administration. It is logical to employ a
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prognostic system such as Ranson, Glasgow, or APACHE-II scores
(Bradley 1993; Dervenis 1999), or CRP levels to increase the
proportion of patients screened for entry into an RCT. However the
use of these criteria alone as a proxy for the presence of pancreatic
necrosis is unwise, as the yield is far from perfect and it is illogical to
evaluate a treatment regimen for its eHect on a condition that study
subjects are not suHering from.
In summary, despite persisting trends of therapeutic benefit, the
addition of more recent, higher quality RCTs leads us to recommend
only that further research is needed. The only statistically
significant benefit observed was in the reduction of infection of the
pancreatic necrosis in the imipenem subgroup, which may be of
value but was not associated with any significant eHect on overall
mortality. It is in the nature of studies of events with low frequency
end-points that individual studies are consistently underpowered.
Until further RCTs are carried out, the data from the present
meta-analysis does not support routine prescribing of antibiotic
prophylaxis in established pancreatic necrosis complicating acute
pancreatitis.
Implications for research
A firm recommendation of the review is that further high quality,
double-blinded placebo-controlled RCTs are required to examine
the significance of trends towards positive therapeutic benefit.
Trial design should also consider the duration of therapy and
adopt consistent stopping rules. Sample size and therefore
statistical power must take account of the ethical use of the
need to 'crossover' to active, non-trial treatment, should antibiotic
treatment become mandatory as part of the management of
established sepsis. Greater detail should be obtained on the
outcome of attacks of varying aetiology. More accurate definitions
should be provided for non-pancreatic infections, and a clear
distinction must be drawn between infected pancreatic necrosis
and infected peripancreatic fluid collections (Beger 1986; Fedorak
1992). Adequate data should also be sought on adverse eHects,
such as the induction of bacterial resistance and the development
of opportunistic fungal infection.
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Methods Randomised, placebo-controlled, double-blind trial. 
Method of randomisation: random computerised allocation. 
Complete follow-up: yes. 
Comparable groups: yes.
Participants 100 patients with severe AP and proven pancreatic necrosis on CT, or Balthazar grade E with either CR-
P>120mg/L or MOD score of >2. 
Setting: Multicenter (US and Europe) 
February 2003 - December 2004
Interventions 50 patients received supportive treatment, and meropenem (1g every 8 hours) for a minimum of 7 days
and a maximum of 21 days (recommended duration 14 days). The other 50 received supportive treat-
ment and placebo. 31 patients in the treatment group, and 32 in the placebo group, received the study
drug for less than 14 days. 11 patients in the meropenem group, and 10 in the placebo group, had the
drug stopped because of diagnosis of infection and starting of non-study antibiotics or surgery.
Outcomes Main end-point: Reduction of pancreatic/peripancreatic infection. 




Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Sequential sealed envelopes with numbers randomly generated by a comput-
er software opened by pharmacist preparing the placebo or meropenem solu-
tion when patient enrolled into the study.
Allocation concealment? Low risk Adequate
Blinding? 
All outcomes
Low risk Opaque zip-lock covers placed over infusion bags, and transparent yellow ad-




Methods Randomised, placebo-controlled, double-blind trial. 
Method of randomisation: consecutive numbers. 
Complete follow-up: yes. 
Comparable groups: yes
Participants 76 patients with severe AP and pancreatic necrosis on CT. 
Severity based on Atlanta Criteria, CRP and CT. 
Setting: Multicenter (Germany) 
January 1999 - June 2002
Interventions 41 patients (median age 49.4) received supportive treatment and prophylactic antibiotics (ciprofloxacin
400mg iv bd, and metronidazole 500mg iv bd). In 15 of these the study medication was discontinued
before the intended 21 days of treatment, these were cases with progressive pancreatitis characterized
by clinical deterioration and/or cases with proven or strongly suspected pancreatic or extrapancreat-
ic infection. The choice of antibiotic was up to the investigator's discretion, although the recommenda-
tion of the study protocol was to use imipenem, in combination with vancomycin where necessary. 
35 patients (median age 46.5) were allocated to the placebo group. They received supportive treat-
ment and placebo. Of these 20 were switched to an open antibiotic regime for the reasons explained
above.
Isenmann 2004 
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Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Stratified randomisation plan generated prior to commencement of study, us-
ing a block size of 4 patients. Sequential allocation.
Allocation concealment? Low risk Adequate
Blinding? 
All outcomes
Low risk Study medication packed in identical vials and labelled with consecutive pa-




Methods Randomised Controlled Trial. 
Method of randomisation: Not stated. 
Complete follow-up: yes. 
Comparable groups: yes.
Participants 58 patients with severe acute pancreatitis and pancreatic necrosis. 
Severity based on CRP concentration > 150mg/L and CT. 
Setting: Tampere, Finland. 
September 1995 - May 1999.
Interventions 33 patients (age 46 +/- 7) received supportive treatment without prophylactic antibiotics. Of these,
Imipenem was started when clinically indicated (consistent increase in inflammatory markers or posi-
tive CT/USS guided FNA of pancreatic necrosis) in 14 patients, of whom 5 needed necrosectomy at least
3 days later. 
25 patients (age 47 +/- 8) received supportive treatment and prophylactic antibiotics (imipenem 1g iv
tds). The duration of the prophylactic antibiotic regimen was not stated in the study.
Outcomes Main end-point: Indication for necrosectomy due to infection. 
Mortality. 
Morbidity. 




Bias Authors' judgement Support for judgement
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Adequate sequence gener-
ation?
Unclear risk Not stated







Methods Randomized Controlled Trial. 
Method of Randomization: Casual numbers table. 
Complete follow-up: yes. 
Comparable groups: yes.
Participants 74 patients with severe acute pancreatitis and pancreatic necrosis proven on CT. 
Setting: 6 Italian centres. 
January 1989 - July 1991.
Interventions 33 patients (mean age 50) received intensive medical treatment with no prophylactic antibiotics. 
41 patients (mean age 54) received intensive medical treatment with prophylactic antibiotics (imipen-
em 500mg iv tds) for 14 days from CT demonstration of pancreatic necrosis.






Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Casual numbers table







Methods Randomised Controlled Trial. 
Method of Randomization: Not stated 
Complete follow-up: yes. 
Comparable groups: yes.
Participants 73 patients with severe acute pancreatitis (necrosis demonstrated on CT and/or elevated serum CRP) 
Setting: 7 Hospitals in Norway. 1997 - 2002.
Røkke 2007 
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Interventions 36 patients received early antibiotic treatment with imipenem (500mg iv tds), and 37 patients received
antibiotics only when clinically indicated.
Outcomes Reduction of septic complications, and delay on the onset of infection was postponed to the 3rd week
in the treatment group.
Notes Unblinded
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Not stated.







Methods Randomized Controlled Trial. 
Method of Randomization: Numbered envelopes. 
Complete follow-up: yes. 
Comparable groups: yes.
Participants 60 patients with severe alcohol induced acute pancreatitis, raised CRP > 120mg/L, and CT proven pan-
creatic necrosis. 
Setting: Helsinki, Finland. 
July 1989 - November 1993.
Interventions 30 patients (age 38.7 +/- 8.4) received supportive medical treatment with antibiotics started only when
clinically, microbiologically or radiologically indicated or when there was a secondary raise in the CRP >
20% after the acute phase.
30 patients (age 43.0 +/- 11.3) received supportive medical treatment and prophylactic antibiotics (ce-
furoxime 1.5g iv tds) from admission and until clinical recovery and fall to normal CRP concentration; in
cases of clinical recovery but moderately raised CRP concentration oral antibiotics (cefuroxime 250mg
p.o. bd) were continued for 14 days.
Outcomes Incidence of pancreatic sepsis. 
Other infections. 
Necrosectomy. 





Bias Authors' judgement Support for judgement
Sainio 1995 
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Adequate sequence gener-
ation?
Unclear risk Sequential sealed envelopes







Methods Randomized Controlled Trial. 
Method of Randomization: Not stated. 
Complete follow-up: yes. 
Comparable groups: yes.
Participants 26 patients with severe acute pancreatitis (?Atlanta criteria). 
Setting: Ulm University Hospital, Germany. 
August 1991 - October 1994.
Interventions 13 patients with severe AP and sterile necrosis (mean age 46 [24-71]) received supportive medical treat-
ment with antibiotics started only when clinically indicated or evidence of infection of the necrotic
pancreatic tissue was obtained.
13 patients with severe AP and sterile necrosis (mean age 43 [31 - 82]) received supportive medical
treatment and prophylactic antibiotics (ofloxacin 200mg b.d. i.v. and metronidazole 500mg b.d. i.v.) for
10 days.
Outcomes Mortality. 




Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Unclear risk Not stated





Glossary of abbreviated terms
AP : Acute Pancreatitis ; b.d.: Bis die (Latin for 'twice a day'); CRP: C Reactive Protein; CT: Computerised Tomography; FNA: Fine Needle
Aspiration; i.v.: intravenously; MOD: Multiple Organ Dysfunction; p.o.: Per os (Latin for 'by mouth'); t.d.s.: Ter die sumendus (Latin for
"three times a day"); USS: Ultrasound scan.
 
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Bassi 1998 Assesses the use of pefloxacin versus imipenem in severe acute pancreatitis, with no control group.
Craig 1975 This is an RCT looking into the efficacy of ampicillin in the treatment of acute pancreatitis. Pub-
lished in 1975 dates from the pre-CT era, and included participants with varying degrees of severity
of acute pancreatitis.
Delcenserie 1996 This is an RCT looking into the role of prophylactic antibiotics in severe acute pancreatitis with one
or more collections demonstrated on CT but with no mention of pancreatic necrosis, therefore not
meeting the inclusion criteria set out in our protocol.
Finch 1976 RCT published in 1976, pre-CT era, looking into the use of ampicillin in acute pancreatitis with vary-
ing degrees of severity.
Gelfand 2001 Only one arm in the study assessing pefloxacin in pancreatonecrosis. No control group.
Howes 1975 Another RCT published in 1975, pre-CT era, looking into the use of ampicillin in acute pancreatitis
with varying degrees of severity.
Imaizumi 2004 Does not assess antibiotic prophylaxis alone, but together with protease inhibitors. These are de-
livered via continuous regional arterial infusion.
Luiten 1995 This is a multicenter RCT evaluating the role of prophylactic antibiotics with selective gut deconta-
mination in severe acute pancreatitis. Criteria for admission was a CT Balthazar grade D or E, which
does not comment on pancreatic necrosis.
Manes 2006 Compares two groups receiving antibiotics (meropenem) started early or late in the disease, with
no control (no antibiotic) group.
Maravi-Poma 2003 Assesses two different concentrations of imipenem with cilastatin as prophylaxis in necrotising
pancreatitis, with no control group.
Takeda 1996 Does not assess antibiotic prophylaxis alone, but together with protease inhibitors. These are de-
livered via continuous regional arterial infusion.
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Methods Randomized Controlled Trial. 
Method of Randomization: Not stated. 
Complete follow-up: yes. 
Comparable groups: yes.
Participants 63 participants with severe acute pancreatitis (Atlanta criteria or CRP>150mg/l). 
Setting: Multicentre - Czech Republic. 
1999 - 2001.
Interventions 30 participants with severe acute pancreatitis received supportive medical treatment with antibi-
otics started only when clinically indicated.
33 participants with severe acute pancreatitis received supportive medical treatment and prophy-
lactic antibiotics (ciprofloxacin 200mg b.d. i.v. and metronidazole 500mg b.d. i.v.).
Outcomes Mortality.
Incidence of pancreatic sepsis.
Hospital stay
Notes Unable to extract number of participants with necrotising pancreatitis after enquiries to authors,




Methods Randomized Controlled Trial. 
Method of Randomization: Not stated. 
Complete follow-up: Not stated. 
Comparable groups: Not stated.
Participants 41 participants with severe acute pancreatitis (Atlanta criteria or CRP>190mg/l). 
Setting: Multicentre - Czech Republic. 
Time period not stated.
Interventions 20 participants with severe acute pancreatitis received supportive medical treatment with antibi-
otics started only when clinically indicated.
21 participants with severe acute pancreatitis received supportive medical treatment and prophy-
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Notes Unable to extract number of participants with necrotising pancreatitis after enquiries to authors,




Methods Randomized Controlled Trial. 
Method of Randomization: Not stated. 
Complete follow-up: Not stated. 
Comparable groups: Not stated.
Participants 35 participants with acute necrotising pancreatitis (CT or autopsy). 
Setting: Multicentre - Czech Republic. 
Time period not stated.
Interventions 17 participants with acute necrotising pancreatitis received supportive medical treatment with an-
tibiotics started only when clinically indicated.
18 participants with acute necrotising pancreatitis received supportive medical treatment and
prophylactic antibiotics (either ciprofloxacin 200mg b.d. iv and metronidazole 500mg i.v. t.d.s. or






Notes This report appears to incorporate data from participants in both studies previously published by
the authors. Enquiries for further information have been unsuccessful, therefore this study was not
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D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Antibiotics versus control





Statistical method Effect size
1 Mortality 7 404 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.34, 1.05]
2 Infected Pancreatic Necrosis 7 404 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.57, 1.26]
3 Non-Pancreatic Infections 5 318 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.36, 1.06]
4 All sites infections 5 318 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.44, 1.09]
5 Fungal Infection 7 404 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.41, 2.70]
6 Operative Treatment 6 378 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.62, 1.31]
 
 
Analysis 1.1.   Comparison 1 Antibiotics versus control, Outcome 1 Mortality.
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Pederzoli 1993 3/41 4/33 15.14% 0.6[0.15,2.51]
Sainio 1995 1/30 7/30 23.91% 0.14[0.02,1.09]
Schwarz 1997 0/13 2/13 8.54% 0.2[0.01,3.8]
Nordback 2001 2/25 5/33 14.72% 0.53[0.11,2.5]
Isenmann 2004 3/41 4/35 14.74% 0.64[0.15,2.67]
Dellinger 2007 6/41 5/41 17.08% 1.2[0.4,3.62]
Røkke 2007 2/12 2/16 5.86% 1.33[0.22,8.16]
   
Total (95% CI) 203 201 100% 0.6[0.34,1.05]
Total events: 17 (Antibiotics), 29 (Control)  
Heterogeneity: Tau2=0; Chi2=4.75, df=6(P=0.58); I2=0%  
Test for overall effect: Z=1.8(P=0.07)  
Favours treatment 200.05 50.2 1 Favours control
 
 
Analysis 1.2.   Comparison 1 Antibiotics versus control, Outcome 2 Infected Pancreatic Necrosis.
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 5/41 10/33 14.23% 0.4[0.15,1.06]
Sainio 1995 9/30 12/30 24.29% 0.75[0.37,1.51]
Schwarz 1997 8/13 7/13 26.49% 1.14[0.59,2.22]
Nordback 2001 1/25 6/33 3.56% 0.22[0.03,1.71]
Isenmann 2004 7/41 5/35 12.3% 1.2[0.42,3.43]
Dellinger 2007 8/41 5/41 12.84% 1.6[0.57,4.48]
Favours treatment 100.1 50.2 20.5 1 Favours control
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Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Røkke 2007 2/12 4/16 6.29% 0.67[0.15,3.06]
   
Total (95% CI) 203 201 100% 0.85[0.57,1.26]
Total events: 40 (Antibiotics), 49 (Control)  
Heterogeneity: Tau2=0.04; Chi2=6.94, df=6(P=0.33); I2=13.49%  
Test for overall effect: Z=0.8(P=0.42)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.3.   Comparison 1 Antibiotics versus control, Outcome 3 Non-Pancreatic Infections.
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 6/41 16/33 22.38% 0.3[0.13,0.68]
Nordback 2001 4/25 1/33 5.62% 5.28[0.63,44.38]
Isenmann 2004 13/41 17/35 30.74% 0.65[0.37,1.15]
Røkke 2007 2/12 6/16 11.03% 0.44[0.11,1.83]
Dellinger 2007 13/41 17/41 30.23% 0.76[0.43,1.36]
   
Total (95% CI) 160 158 100% 0.62[0.36,1.06]
Total events: 38 (Antibiotics), 57 (Control)  
Heterogeneity: Tau2=0.16; Chi2=7.61, df=4(P=0.11); I2=47.47%  
Test for overall effect: Z=1.73(P=0.08)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.4.   Comparison 1 Antibiotics versus control, Outcome 4 All sites infections.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 11/41 26/33 22.65% 0.34[0.2,0.58]
Nordback 2001 5/25 7/33 12.42% 0.94[0.34,2.62]
Isenmann 2004 19/41 17/35 24.29% 0.95[0.59,1.53]
Dellinger 2007 21/41 22/41 25.93% 0.95[0.63,1.44]
Røkke 2007 4/12 10/16 14.71% 0.53[0.22,1.29]
   
Total (95% CI) 160 158 100% 0.69[0.44,1.09]
Total events: 60 (Treatment), 82 (Control)  
Heterogeneity: Tau2=0.17; Chi2=11.46, df=4(P=0.02); I2=65.09%  
Test for overall effect: Z=1.58(P=0.12)  
Favours treatment 100.1 50.2 20.5 1 Favours control
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Analysis 1.5.   Comparison 1 Antibiotics versus control, Outcome 5 Fungal Infection.
Study or subgroup Antibiotics Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 0/41 4/33 10.61% 0.09[0.01,1.61]
Sainio 1995 1/30 0/30 8.84% 3[0.13,70.83]
Schwarz 1997 3/13 2/13 33.86% 1.5[0.3,7.55]
Nordback 2001 1/25 0/33 8.85% 3.92[0.17,92.43]
Isenmann 2004 1/41 1/35 11.82% 0.85[0.06,13.15]
Dellinger 2007 2/41 1/41 15.85% 2[0.19,21.21]
Røkke 2007 0/12 2/16 10.16% 0.26[0.01,4.99]
   
Total (95% CI) 203 201 100% 1.06[0.41,2.7]
Total events: 8 (Antibiotics), 10 (Control)  
Heterogeneity: Tau2=0; Chi2=5.47, df=6(P=0.49); I2=0%  
Test for overall effect: Z=0.11(P=0.91)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.6.   Comparison 1 Antibiotics versus control, Outcome 6 Operative Treatment.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 12/41 11/33 29.97% 0.88[0.45,1.73]
Sainio 1995 7/30 14/30 24.38% 0.5[0.24,1.06]
Nordback 2001 2/25 5/33 5.8% 0.53[0.11,2.5]
Isenmann 2004 10/41 6/35 16.94% 1.42[0.57,3.52]
Røkke 2007 2/12 2/16 4.28% 1.33[0.22,8.16]
Dellinger 2007 10/41 7/41 18.63% 1.43[0.6,3.39]
   
Total (95% CI) 190 188 100% 0.9[0.62,1.31]
Total events: 43 (Treatment), 45 (Control)  
Heterogeneity: Tau2=0; Chi2=5.06, df=5(P=0.41); I2=1.23%  
Test for overall effect: Z=0.56(P=0.58)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Comparison 2.   Beta-lactam versus control





Statistical method Effect size
1 Mortality (beta-lactam) 5 302 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.37, 1.40]
2 Infected Pancreatic Necrosis (be-
ta-lactam)
5 302 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.40, 1.19]
3 Non-Pancreatic Infections (be-
ta-lactam)
4 242 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.28, 1.47]
4 All sites infections (beta-lactam) 4 242 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.35, 1.13]
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Statistical method Effect size
5 Fungal Infection (beta-lactam) 5 302 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.21, 3.76]
6 Operative Treatment (beta-lac-
tam)
5 302 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.54, 1.23]
 
 
Analysis 2.1.   Comparison 2 Beta-lactam versus control, Outcome 1 Mortality (beta-lactam).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 3/41 4/33 21.71% 0.6[0.15,2.51]
Sainio 1995 1/30 7/30 10.74% 0.14[0.02,1.09]
Nordback 2001 2/25 5/33 18.27% 0.53[0.11,2.5]
Røkke 2007 2/12 2/16 13.51% 1.33[0.22,8.16]
Dellinger 2007 6/41 5/41 35.78% 1.2[0.4,3.62]
   
Total (95% CI) 149 153 100% 0.72[0.37,1.4]
Total events: 14 (Treatment), 23 (Control)  
Heterogeneity: Tau2=0.01; Chi2=4.05, df=4(P=0.4); I2=1.21%  
Test for overall effect: Z=0.97(P=0.33)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 2.2.   Comparison 2 Beta-lactam versus control, Outcome 2 Infected Pancreatic Necrosis (beta-lactam).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 5/41 10/33 23.63% 0.4[0.15,1.06]
Sainio 1995 9/30 12/30 37.07% 0.75[0.37,1.51]
Nordback 2001 1/25 6/33 6.52% 0.22[0.03,1.71]
Røkke 2007 2/12 4/16 11.21% 0.67[0.15,3.06]
Dellinger 2007 8/41 5/41 21.57% 1.6[0.57,4.48]
   
Total (95% CI) 149 153 100% 0.69[0.4,1.19]
Total events: 25 (Treatment), 37 (Control)  
Heterogeneity: Tau2=0.08; Chi2=5.01, df=4(P=0.29); I2=20.21%  
Test for overall effect: Z=1.32(P=0.19)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 2.3.   Comparison 2 Beta-lactam versus control, Outcome 3 Non-Pancreatic Infections (beta-lactam).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 6/41 16/33 31.59% 0.3[0.13,0.68]
Nordback 2001 4/25 1/33 11.45% 5.28[0.63,44.38]
Favours treatment 100.1 50.2 20.5 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Røkke 2007 2/12 6/16 19.67% 0.44[0.11,1.83]
Dellinger 2007 13/41 17/41 37.3% 0.76[0.43,1.36]
   
Total (95% CI) 119 123 100% 0.64[0.28,1.47]
Total events: 25 (Treatment), 40 (Control)  
Heterogeneity: Tau2=0.4; Chi2=7.58, df=3(P=0.06); I2=60.4%  
Test for overall effect: Z=1.05(P=0.29)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 2.4.   Comparison 2 Beta-lactam versus control, Outcome 4 All sites infections (beta-lactam).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 11/41 26/33 29.18% 0.34[0.2,0.58]
Nordback 2001 5/25 7/33 17.87% 0.94[0.34,2.62]
Dellinger 2007 21/41 22/41 32.32% 0.95[0.63,1.44]
Røkke 2007 4/12 10/16 20.63% 0.53[0.22,1.29]
   
Total (95% CI) 119 123 100% 0.63[0.35,1.13]
Total events: 41 (Treatment), 65 (Control)  
Heterogeneity: Tau2=0.24; Chi2=9.71, df=3(P=0.02); I2=69.11%  
Test for overall effect: Z=1.56(P=0.12)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 2.5.   Comparison 2 Beta-lactam versus control, Outcome 5 Fungal Infection (beta-lactam).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 0/41 4/33 19.81% 0.09[0.01,1.61]
Sainio 1995 1/30 0/30 17.13% 3[0.13,70.83]
Nordback 2001 1/25 0/33 17.15% 3.92[0.17,92.43]
Røkke 2007 0/12 2/16 19.15% 0.26[0.01,4.99]
Dellinger 2007 2/41 1/41 26.76% 2[0.19,21.21]
   
Total (95% CI) 149 153 100% 0.88[0.21,3.76]
Total events: 4 (Treatment), 7 (Control)  
Heterogeneity: Tau2=0.6; Chi2=5.11, df=4(P=0.28); I2=21.74%  
Test for overall effect: Z=0.17(P=0.86)  
Favours treatment 100.1 50.2 20.5 1 Favours control
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Analysis 2.6.   Comparison 2 Beta-lactam versus control, Outcome 6 Operative Treatment (beta-lactam).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 12/41 11/33 36.29% 0.88[0.45,1.73]
Sainio 1995 7/30 14/30 29.39% 0.5[0.24,1.06]
Nordback 2001 2/25 5/33 6.89% 0.53[0.11,2.5]
Røkke 2007 2/12 2/16 5.08% 1.33[0.22,8.16]
Dellinger 2007 10/41 7/41 22.35% 1.43[0.6,3.39]
   
Total (95% CI) 149 153 100% 0.82[0.54,1.23]
Total events: 33 (Treatment), 39 (Control)  
Heterogeneity: Tau2=0; Chi2=3.87, df=4(P=0.42); I2=0%  
Test for overall effect: Z=0.96(P=0.34)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Comparison 3.   Quinolone versus control





Statistical method Effect size
1 Mortality (quinolones) 2 102 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.14, 1.85]
2 Infected Pancreatic Necrosis
(quinolones)
2 102 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.66, 2.03]
3 Fungal Infection (quinolones) 2 102 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.32, 5.21]
 
 
Analysis 3.1.   Comparison 3 Quinolone versus control, Outcome 1 Mortality (quinolones).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Schwarz 1997 0/13 2/13 19.03% 0.2[0.01,3.8]
Isenmann 2004 3/41 4/35 80.97% 0.64[0.15,2.67]
   
Total (95% CI) 54 48 100% 0.51[0.14,1.85]
Total events: 3 (Treatment), 6 (Control)  
Heterogeneity: Tau2=0; Chi2=0.5, df=1(P=0.48); I2=0%  
Test for overall effect: Z=1.02(P=0.31)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 3.2.   Comparison 3 Quinolone versus control, Outcome 2 Infected Pancreatic Necrosis (quinolones).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Schwarz 1997 8/13 7/13 71.77% 1.14[0.59,2.22]
Favours treatment 100.1 50.2 20.5 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Isenmann 2004 7/41 5/35 28.23% 1.2[0.42,3.43]
   
Total (95% CI) 54 48 100% 1.16[0.66,2.03]
Total events: 15 (Treatment), 12 (Control)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.94); I2=0%  
Test for overall effect: Z=0.51(P=0.61)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 3.3.   Comparison 3 Quinolone versus control, Outcome 3 Fungal Infection (quinolones).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Schwarz 1997 3/13 2/13 74.13% 1.5[0.3,7.55]
Isenmann 2004 1/41 1/35 25.87% 0.85[0.06,13.15]
   
Total (95% CI) 54 48 100% 1.3[0.32,5.21]
Total events: 4 (Treatment), 3 (Control)  
Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.73); I2=0%  
Test for overall effect: Z=0.37(P=0.71)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Comparison 4.   Imipenem versus control





Statistical method Effect size
1 Mortality (imipenem) 3 160 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.28, 1.75]
2 Infected Pancreatic Necrosis
(imipenem)
3 160 Odds Ratio (M-H, Random, 95% CI) 0.34 [0.13, 0.84]
3 Non-pancreatic infections
(imipenem)
3 160 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.16, 2.77]
4 All sites infections (imipenem) 3 160 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.28, 0.87]
5 Fungal Infection (imipenem) 3 160 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.05, 3.64]
6 Operative Treatment (imipen-
em)
3 160 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.47, 1.54]
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Analysis 4.1.   Comparison 4 Imipenem versus control, Outcome 1 Mortality (imipenem).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 3/41 4/33 40.68% 0.6[0.15,2.51]
Nordback 2001 2/25 5/33 34.15% 0.53[0.11,2.5]
Røkke 2007 2/12 2/16 25.17% 1.33[0.22,8.16]
   
Total (95% CI) 78 82 100% 0.7[0.28,1.75]
Total events: 7 (Treatment), 11 (Control)  
Heterogeneity: Tau2=0; Chi2=0.66, df=2(P=0.72); I2=0%  
Test for overall effect: Z=0.76(P=0.45)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 4.2.   Comparison 4 Imipenem versus control, Outcome 2 Infected Pancreatic Necrosis (imipenem).
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 5/41 10/33 58.97% 0.32[0.1,1.05]
Nordback 2001 1/25 6/33 17.58% 0.19[0.02,1.67]
Røkke 2007 2/12 4/16 23.46% 0.6[0.09,3.99]
   
Total (95% CI) 78 82 100% 0.34[0.13,0.84]
Total events: 8 (Treatment), 20 (Control)  
Heterogeneity: Tau2=0; Chi2=0.64, df=2(P=0.72); I2=0%  
Test for overall effect: Z=2.32(P=0.02)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 4.3.   Comparison 4 Imipenem versus control, Outcome 3 Non-pancreatic infections (imipenem).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 6/41 16/33 43.03% 0.3[0.13,0.68]
Nordback 2001 4/25 1/33 23.51% 5.28[0.63,44.38]
Røkke 2007 2/12 6/16 33.46% 0.44[0.11,1.83]
   
Total (95% CI) 78 82 100% 0.67[0.16,2.77]
Total events: 12 (Treatment), 23 (Control)  
Heterogeneity: Tau2=1.04; Chi2=6.26, df=2(P=0.04); I2=68.06%  
Test for overall effect: Z=0.55(P=0.58)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 4.4.   Comparison 4 Imipenem versus control, Outcome 4 All sites infections (imipenem).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 11/41 26/33 48.91% 0.34[0.2,0.58]
Favours treatment 100.1 50.2 20.5 1 Favours control
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Nordback 2001 5/25 7/33 22.97% 0.94[0.34,2.62]
Røkke 2007 4/12 10/16 28.12% 0.53[0.22,1.29]
   
Total (95% CI) 78 82 100% 0.49[0.28,0.87]
Total events: 20 (Treatment), 43 (Control)  
Heterogeneity: Tau2=0.1; Chi2=3.22, df=2(P=0.2); I2=37.8%  
Test for overall effect: Z=2.45(P=0.01)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 4.5.   Comparison 4 Imipenem versus control, Outcome 5 Fungal Infection (imipenem).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 0/41 4/33 34.92% 0.09[0.01,1.61]
Nordback 2001 1/25 0/33 31.09% 3.92[0.17,92.43]
Røkke 2007 0/12 2/16 33.99% 0.26[0.01,4.99]
   
Total (95% CI) 78 82 100% 0.42[0.05,3.64]
Total events: 1 (Treatment), 6 (Control)  
Heterogeneity: Tau2=1.32; Chi2=3.13, df=2(P=0.21); I2=36.07%  
Test for overall effect: Z=0.79(P=0.43)  
Favours treatment 100.1 50.2 20.5 1 Favours control
 
 
Analysis 4.6.   Comparison 4 Imipenem versus control, Outcome 6 Operative Treatment (imipenem).
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Pederzoli 1993 12/41 11/33 75.2% 0.88[0.45,1.73]
Nordback 2001 2/25 5/33 14.28% 0.53[0.11,2.5]
Røkke 2007 2/12 2/16 10.52% 1.33[0.22,8.16]
   
Total (95% CI) 78 82 100% 0.85[0.47,1.54]
Total events: 16 (Treatment), 18 (Control)  
Heterogeneity: Tau2=0; Chi2=0.61, df=2(P=0.74); I2=0%  
Test for overall effect: Z=0.53(P=0.6)  
Favours treatment 100.1 50.2 20.5 1 Favours control
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Date Event Description
3 March 2010 New citation required and conclusions
have changed
Updated, new authors, new studies added, conclusions changed.
16 September 2009 New search has been performed Updated.
 
H I S T O R Y
Protocol first published: Issue 1, 2001
Review first published: Issue 4, 2003
 
Date Event Description
15 August 2009 New citation required and conclusions
have changed
Substantive amendment
25 June 2009 Amended Converted to new review format.
11 June 2008 New search has been performed Conclusions changed, feedback added, minor update.
1 February 2008 New search has been performed New studies found and included or excluded.
1 October 2007 New search has been performed New studies found but not yet included or excluded.
24 January 2005 Amended Reformatted.
 
C O N T R I B U T I O N S   O F   A U T H O R S
Claudio Bassi wrote a draO protocol for this study. Mike Larvin developed this for inclusion in the Cochrane Library. Eduardo Villatoro
and Mike Larvin implemented the initial review (Villatoro 2003), and the 2006 revision (Villatoro 2006). Mubashir Mulla assisted Eduardo
Villatoro and Mike Larvin with the present version of the review.
Study costs were met by the Academic Division of Surgery, School of Graduate Entry Medicine and Health, University of Nottingham, Derby
(http://www.nottingham.ac.uk/mhs/gem), aHiliated to the University's Wolfson Digestive Diseases Centre (http://www.nottingham.ac.uk/
wddc)
Fellowships for Eduardo Villatoro and Mubashir Mulla were funded by the Royal Derby Hospital NHS Foundation Trust. (http://
www.derbyhospitals.nhs.uk).
D E C L A R A T I O N S   O F   I N T E R E S T
Professor Claudio Bassi was a co-author of one of the RCTs reviewed (Pederzoli 1993), but did not participate in the meta-analysis,
discussion or conclusions. Professor Mike Larvin and Dr Eduardo Villatoro participated in the later stages of the international multi-centre
study on the role of meropenem for prophylaxis against infection in pancreatic necrosis (Dellinger 2007). The study was sponsored by Astra-
Zeneca who covered local administrative costs, and attendance for both at a mid-study conference during 2004. Neither investigator has
received personal remuneration, nor were they involved as members of the study planning, analysis, or writing committees.
S O U R C E S   O F   S U P P O R T
Internal sources
• Academic Division of Surgery, School of Graduate Entry Medicine and Health, University of Nottingham, Derby, UK.
• Royal Derby Hospital NHS Foundation Trust, Derby, UK.
• Wolfson Digestive Diseases Centre, University of Nottingham, UK.
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External sources
• No sources of support supplied
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We did not originally plan a formal sub-group analysis comparing imipenem plus cilastatin with control, but the availability of data
published in new included studies led us to perform this additional sub-group analysis.
We elected to use risk ratios (RR) in this updated review and we employed a random eHect meta-analysis model (instead of a fixed-eHect
one as in previous versions of this review) for all end-points where there was significant heterogeneity.
N O T E S
The review now includes the studies of Dellinger 2007 and Røkke 2007.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Antibiotic Prophylaxis;  Acute Disease;  Bacterial Infections  [mortality]  [*prevention & control];  Necrosis  [complications];  Pancreas
 [*pathology];  Pancreatitis  [*complications]  [mortality];  Pancreatitis, Acute Necrotizing  [complications];  Randomized Controlled Trials
as Topic;  Superinfection  [*prevention & control]
MeSH check words
Humans
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